Spyre Therapeutics (SYRE) Revenue & Revenue Breakdown
Spyre Therapeutics Revenue Highlights
00
Spyre Therapeutics Revenue by Period
Spyre Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2025-12-31 | - | 100.00% |
| 2024-12-31 | - | -100.00% |
| 2023-12-31 | $886.00K | -61.96% |
| 2022-12-31 | $2.33M | -87.57% |
| 2021-12-31 | $18.74M | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | -100.00% |
| 2018-12-31 | $3.89M | -25.30% |
| 2017-12-31 | $5.21M | 12.47% |
| 2016-12-31 | $4.63M | -23.94% |
| 2015-12-31 | $6.08M | 100.00% |
| 2014-12-31 | - | - |
Spyre Therapeutics generated - in revenue during NA 2025, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Spyre Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2026-09-30 | - | 100.00% |
| 2026-06-30 | - | 100.00% |
| 2026-03-31 | - | -100.00% |
| 2025-12-31 | $90.49M | 100.00% |
| 2025-09-30 | - | 100.00% |
| 2025-06-30 | - | 100.00% |
| 2025-03-31 | - | 100.00% |
| 2024-12-31 | - | 100.00% |
| 2024-09-30 | - | 100.00% |
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | 100.00% |
| 2023-12-31 | - | 100.00% |
| 2023-09-30 | - | -100.00% |
| 2023-06-30 | $688.00K | 247.47% |
| 2023-03-31 | $198.00K | 17.86% |
| 2022-12-31 | $168.00K | -3.45% |
| 2022-09-30 | $174.00K | -72.16% |
| 2022-06-30 | $625.00K | -54.11% |
| 2022-03-31 | $1.36M | -62.62% |
| 2021-12-31 | $3.64M | 160.47% |
| 2021-09-30 | $1.40M | -89.79% |
| 2021-06-30 | $13.70M | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | -100.00% |
| 2018-06-30 | $2.38M | 57.48% |
| 2018-03-31 | $1.51M | 1.89% |
| 2017-12-31 | $1.48M | 17.53% |
| 2017-09-30 | $1.26M | - |
Spyre Therapeutics generated - in revenue during Q3 2026, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Spyre Therapeutics Revenue Breakdown
Spyre Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 |
|---|---|
| License | - |
Latest
Spyre Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ARDX | Ardelyx | $407.32M | $127.66M |
| ANAB | AnaptysBio | $234.60M | $30.27M |
| ACRS | Aclaris Therapeutics | $7.83M | $1.48M |
| ODTX | Odyssey Therapeutics | $2.98M | - |
| UPB | Upstream Bio | $2.85M | $395.00K |
| IFRX | InflaRx | $61.80K | $36.25K |
| AGMB | AgomAb Therapeutics N.V. American Depositary Shares | - | - |
| SYRE | Spyre Therapeutics | - | - |
| IMUX | Immunic | - | - |
| ABVX | Abivax | - | - |